bluuebunny/crossref_metadata_2025_split huggingface dataset:
P0560 Levels of disease-associated anti-integrin αVβ6 are substantially reduced after proctocolectomy in ulcerative colitis but persist in primary sclerosing cholangitis
Authors: Roth D , Düll M , Horst L , Lindemann A , Elsner X , Koop K , Zundler S , Vetter M , Jefremow A , Atreya R , Geppert C , Weidemann S , Waldner M , Dietrich P , Günther C , Munoz L , Herrmann M , Neurath M , Siebler J , Schramm C , Kremer A , Leppkes M 
Published: January 2025

Abstract

Background
Recently, autoantibodies directed against the epithelial adhesion protein integrin αVβ6 have been identified that strongly associate with ulcerative colitis (UC) and primary sclerosing cholangitis (PSC) with potential disease-driving effects. The presence of anti-αVβ6 in PSC without IBD is under debate. Moreover, data on the effect of proctocolectomy on autoantibody levels remains scarce.

Methods
Anti-αVβ6-directed autoantibodies were detected by a commercial enzyme-linked immunosorbent assay in patient sera, including healthy controls (N = 62), ulcerative colitis (N = 36), Crohn’s disease (CD, N = 65), PSC with concomitant IBD (78 samples from N = 41 patients), PSC without clinically manifest IBD (41 samples from N = 18 patients). Additionally, sera after proctocolectomy were studied (44 samples / N= 10 patients: 5 with UC, 5 with PSC). Immunofluorescent analyses of the target autoantigen were performed in liver, large bile ducts from surgical resections and colon tissue samples of PSC patients and single-cell RNA seq datasets were studied.

Results
The target autoantigen is expressed in disease-associated epithelia in the colon, in cholangiocytes in fibrotic portal fields and periductular glands of the large bile ducts as detected in immunofluorescence and single-cell RNA sequencing datasets. Anti-αVβ6 antibodies occur in 74% of patients with PSC with IBD, but also in 39% of patients with PSC without manifest IBD with lower levels. Anti-αVβ6 levels correlate with intestinal disease activity in patients with primary sclerosing cholangitis. Interestingly, proctocolectomy reduces autoantibody levels more strongly in UC than in PSC patients.

Conclusion
Disease-associated anti-integrin αVβ6 autoantibodies are also present in PSC without IBD with lower levels, assay sensitivity being a crucial determinant of detection. Moreover, proctocolectomy more strongly reduced autoantibody levels in UC than in PSC. Preferential autoantibody persistence in PSC after proctocolectomy might explain the increased incidence of chronic pouchitis in PSC.
P0566 Submucosal, but not mucosal, wall thickness and stiffness correlate with bowel urgency in Ulcerative Colitis
Authors: Serizawa K , Sagami MD- PhD S , Shibui S , Umeda S , Asonuma K , Komatsu M , Maeda M , Nogami A , Karashima R , Nakano M , Maeda I , Hibi T , Kobayashi T 
Published: January 2025

Abstract

Background
Patients with ulcerative colitis (UC) may have bowel urgency (BU), which has been recognised as important due to its links with anxiety, depression, and reduced social quality of life. This study examines intestinal ultrasound (IUS) findings associated with BU, comparing them to endoscopic findings and biomarkers.

Methods
This prospective, single-centre study included UC patients undergoing colonoscopy from January to September 2023. Transabdominal and transperineal IUS was performed, assessing bowel wall thickness (BWT), colour Doppler signal (CDS), and shear wave elastography (SWE) in the sigmoid colon. The thickness of each layer of the sigmoid colon was also measured. Patients were grouped by urgency status per the Simple Clinical Colitis Activity Index. Statistical methods included the Wilcoxon rank-sum test, logistic regression, and ROC curve analysis.

Results
A total of 59 patients were enrolled, of which 33 patients (56%) had BU. CRP, MES, BWT (descending, sigmoid colon and rectum), thickness of submucosa and muscularis propria, CDS (sigmoid and rectum), and SWE were significantly higher (P&lt;0.05) in patients with BU, while faecal calprotectin (FC). was not different (P=0.48). Logistic regression adjusted for MES identified BWT (sigmoid and rectum) and SWE as factors associated with BU. Interestingly, thickness of submucosa (p&lt;0.01) and muscularis propria (P=0.03) but not mucosal layer (P=0.97) correlates with BU (Table). ROC analysis showed that thickness of submucosa predicted BU with high accuracy, outperforming mucosal thickness (P&lt;0.05) (Figure).

Conclusion
Sigmoid BWT, especially submucosal thickness and wall stiffness assessed via IUS, correlates strongly with BU, independent of endoscopic severity. These findings provide important insights into the pathophysiology of BU in UC.
P0571 Transmural healing, assessed through the combination of faecal calprotectin and intestinal ultrasound, is associated with a reduced risk of bowel damage progression in patients with Crohn's disease
Authors: Buisson A , Huet J , Dodel M , Coban D , Bazoge M , Mathieu K , Pereira B 
Published: January 2025

Abstract

Background
Faecal calprotectin (Fcal) and intestinal ultrasound (IUS) could be used as non-invasive tools to monitor Crohn's disease (CD).
We evaluated the agreement between Fcal and IUS in detecting active CD and to explore the complementarity of these tools in predicting long-term outcomes in CD.

Methods
In this prospective study, we consecutively included CD patients who underwent both IUS and Fcal testing within 7 days . IUS was performed by an experienced IBD sonographer, blinded from biological results.
Patients were categorized into four groups: transmural healing (both normal), IUS healing (Fcal &gt;100 μg/g but normal IUS), mucosal healing (Fcal &lt;100 μg/g but abnormal IUS), and no healing (both Fcal and IUS abnormal). IUS was considered abnormal if at least one of the following CD-related findings was present: increased bowel wall thickness (&gt;3 mm), abnormal vascular pattern (color Doppler signal &gt;0), loss of intestinal wall layer stratification, mesenteric fat proliferation, enlarged lymph nodes, or CD-related complications (e.g., strictures, fistulas, or abscesses).
Endpoints were the time to bowel damage progression and the time to relapse-related drug discontinuation.
Agreement was expressed as a percentage and quantified using the κ coefficient. Survival analyses were conducted using the log-rank test (univariate) and Cox regression models (multivariate). 10-points acceptability numerical scale were compared using paired tests.

Results
Among 112 included patients, 44.6% (50/112), 12.5% (14/112), 16.1% (18/112), and 26.8% (30/112) achieved transmural healing, IUS healing, mucosal healing, and no healing, respectively. No significant differences were observed among the four groups. At baseline, 42% (47/112) of patients were symptomatic according to PRO-2.
The agreement between IUS and Fcal for detecting active CD was low (71.4%, κ coefficient = 0.41 ± 0.09). Transmural healing was associated with a reduced risk of bowel damage progression compared to no healing (p &lt;0.0001), unlike IUS healing (p = 0.15) or mucosal healing (p = 0.84) (Figure 1).
Transmural healing was also associated with lower risk of relapse-related drug discontinuation compared to mucosal healing (HR = 0.09 [0.02-0.45], p = 0.003), IUS healing (HR = 0.10 [0.02-0.60], p = 0.001), or no healing (HR = 0.09 [0.018-0.04], p = 0.002).
IUS was better accepted than stool collection for Fcal testing (10 points-acceptability numerical scale = 9.6 ± 0.8 vs. 7.9 ± 2.3; p &lt;0.0001).

Conclusion
Transmural healing, assessed through a combination of non-invasive and well-accepted tools such as Fcal and IUS, is associated with improved long-term outcomes and could be used for monitoring patients with CD in daily practice.
P0573 The Burden of Urgency in Ulcerative Colitis: Impact of Disease Duration and Activity
Authors: Singeap PhD A M , Muzica C , Huiban L , Girleanu I , Stafie R , Minea H , Stanciu C , Trifan A 
Published: January 2025

Abstract

Background
Urgency is a prevalent and distressing symptom in ulcerative colitis (UC) that significantly impairs quality of life. In longstanding UC, urgency often persists even during remission. This study aims to assess the burden of urgency in UC according to disease duration, and to disease activity.

Methods
A cross-sectional study was conducted on 96 UC patients in a tertiary care center, divided into two groups based on disease duration: 45 patients with UC for under 5 years and 51 with UC for over 5 years. Additionally, patients were categorized by disease activity, with 48 patients in remission and 48 experiencing active disease. All participants completed a questionnaire evaluating urgency frequency, severity, and its impact on daily life, while quality of life was assessed using validated scales. Statistical analyses compared urgency burden across both duration and activity groups.

Results
Patients with UC duration over 5 years reported significantly higher urgency severity and greater interference with daily activities, social interactions, and work compared to those with a shorter disease duration (p&lt;0.05). Among all patients in remission, urgency persisted in 45%, with 55% of longstanding patients more likely to report urgency as a significant burden, compared to 39% of patients with more recent disease (under 5 years). Comparatively, urgency was more severe in patients with active disease, but a notable portion of those in remission (particularly in the over-5-year group) continued to experience substantial urgency-related impact.

Conclusion
Urgency remains a considerable burden in patients with UC, persisting in 45% of those in remission and affecting quality of life more significantly in longstanding disease. This elevated frequency and impact in patients with prolonged disease may be attributed to cumulative bowel damage, chronic inflammation, or altered bowel sensitivity over time, even when the disease is in remission. Addressing urgency early in the course of the disease is essential to improving quality of life and preventing the chronic sequelae seen in longstanding UC.
P0576 Ultrasound assessment of sarcopenia and body composition in patients with inflammatory bowel disease
Authors: Akchurina O , Mukhametova D , Bodryagina E , Odintsova A , Abdulganieva D 
Published: January 2025

Abstract

Background
Sarcopenia is a progressive pathological condition which can present in inflammatory bowel disease (IBD) together with changes in body composition.

Aim
To provide ultrasound assessment of muscle mass and bioimpedance analysis of body composition in patients with IBD.

Methods: Material and Method
The study included 102 patients with IBD, 50 (49%) with ulcerative colitis (UC), 52 (51%) with Crohn's disease (CD), 10 persons formed the control group (CG). The average age of patients with IBD was 39,5 [28,5; 50] year, in the CG – 37 [26; 38] years. There were 52 (51%) women in the IBD group and 5 (50%) in CG. Patients underwent an examination with assessment of body mass index (BMI), mid-upper arm circumference (MUAC, cm) and mid-thigh circumference (MTC, cm) of dominant side; bioimpedance analysis of body composition using the ABC-02 “MEDASS” apparatus; ultrasound examination of the muscle thickness (MT) at the following two points of the leading side: ultrasound mid upper arm, ultrasound mid-thigh.

Results
According to BMI, patients were distributed as follows: normal body weight was observed in 57 (55,9%) patients; deficiency – in 12 (11,8%); overweight 25 (24,5%); obesity – 8 (7,8%). The average MUAC values of the dominant hand in women were 28 [24,9; 31] cm, in the CG were 28 [27; 28,5] cm (p&gt;0.05); in men 29,8 [27; 32] cm, in the CG were 33 [31; 34] cm (p&lt;0.05). The average MTC in women with IBD were 54,25 [48,15; 58,1] cm, in the CG were 61,5 [56; 67] cm (p&lt;0.05); in men 48 [46; 51,4] cm, in the CG were 54 [53; 54] cm (p&lt;0.05). The MT in ultrasound mid upper arm in women with IBD was 19,60 [18,23; 22,84] mm, CG 22.49 [20.41; 22.66] (p&gt;0.05); in men with IBD 26,45 [22,87; 29,24] mm, in the CG 21,54 [21,18; 25,13] mm (p&gt;0.05). The MT in ultrasound mid-thigh in women with IBD was 31,05 [23,21; 37,11] mm, CG 41,30 [35,55; 41,74] mm (p&lt;0.05), in men with IBD 30,90 [25,64; 39,99] mm, in the CG 40,67 [39,10; 41,84] (p&lt;0.05). According to the results of bioimpedance, a deficiency of skeletal muscle mass was detected in 31% patients, in 66% patients skeletal muscle mass was normal, excess muscle mass was detected in 3% patients. The MT in ultrasound mid upper arm correlated with MUAC (r=0,557; p&lt;0.05), with BMI (r=0,448; p&lt;0.05), with skeletal muscle mass according to bioimpedancemetry (r=0,666; p&lt;0.05). The MT in ultrasound mid-thigh correlated with MTC (r=0,505; p&lt;0.05), with BMI (r= 0,376; p&lt;0.05), with skeletal muscle mass according to bioimpedancemetry (r=0,373; p&lt;0.05).

Conclusion
In patients with IBD MTC was lower than in CG. The muscle thickness in ultrasound mid-thigh in women and men with IBD was less than in CG, which correlated with MTC, BMI, skeletal muscle mass according to bioimpedancemetry.
P0577 Influence of Pregnancy on Outcomes of Inflammatory Bowel Disease and Medication Adherence
Authors: Ozturk O , Durak M B , Cagir Y , Ergul M , Keskin E T , Atay A , Yuksel I 
Published: January 2025

Abstract

Background
Treatment of inflammatory bowel disease (IBD) is challenging due to the maintenance of remission and associated fetal safety concerns during pregnancy. While existing literature emphasizes the importance of achieving remission prior to conception, optimal management of IBD during pregnancy remains underexplored, especially regarding medication continuation and efficacy.

Methods
This cross-sectional study was performed in pregnant patients with IBD between March 2019 and June 2023. Clinical features, treatment details, disease activation and outcomes were collected and analyzed.

Results
A total of 57 pregnant were included, of those 37 (64.9%) had UC, and 20 (35.1%) had CD. The overall median disease duration was 9.1 (6-12.8) years (8.2 years for UC and 9.9 years for CD). The disease location was 19 (51.4%) left-sided colitis, 15 (40.5%) extensive, and 3 (8.1%) proctitis in UC, while in CD 8 (40%) patients were ileal involvement, 8 (40%) ileocolonic and 4 (20%) colonic. 4 (20%) had stricturing disease and 4 (20%) had penetrating disease in CD. Before pregnancy, medical treatments for UC patients were mesalazine in 29 (78.4%) patients, thiopurine in 20 (54.1%), biologic therapy in 6 (16.2%), while it was 13 (65%) patients biologic therapy and 7 (35%) thiopurine in CD patients. The most prescribed biologic agent was infliximab in both diseases.
During pregnancy, 16 (28.1%) patients [6 (18.8%) with UC and 10 (50%) with CD] had a history of drug withdrawal. 13 (%81) medications were withdrawn by the patient's wish. Disease activation occurred in 25 (43.9%) patients, 10 (50%) with CD, and 15 (40.5%) with UC. 12 (48%) patients required steroids due to activation. There were 54 (94.7%) live births when compared based on whether disease activation developed or not, there was no statistically significant difference in live birth rate 23, 92% vs. 31, 96.9%, p=0.576. There was no statistically significant difference between normal birth and cesarean section rates with activation development. 3 (5%) abortions occurred. Abortion rate was not associated with disease activation (p&gt;0.05). No serious infection occurred during the first month following birth.

Conclusion
In this study, the disease activation was seen in 43.9% of pregnant patients with IBD. Consistent medication management of IBD during pregnancy enhances patient adherence, reduces risks, and promotes positive maternal outcomes. Proactive counseling and careful selection of medications are crucial for disease control and optimizing pregnancy outcomes in IBD patients.
P0578 The relationship between the concentration of D-dimer and interleukin-6 in patients with ulcerative colitis.
Authors: Knyazev O , Kagramanova A V 
Published: January 2025

Abstract

Background
In patients with inflammatory bowel diseases (IBD), there was a more frequent development of thromboembolic complications, which is due to an increased concentration of procoagulants and proinflammatory cytokines.

Aim
to determine the concentration of D-dimer and interleukin-6 (IL-6) in patients with total ulcerative colitis (UC) during the period of exacerbation and remission of the disease and establish a link between them.

Methods
The study included 38 patients with severe total ulcerative colitis (UC) with exacerbation and 40 patients with total ulcerative colitis in remission. The concentration of D-dimer [N=0.0-0.50 mcg/ml] and the concentration of IL-6 [N=0.0-12.7 pg/ml] were determined in all patients. Correlation analysis of IL-6 concentration and D-dimer concentration in UC patients during remission and during exacerbation was carried out.

Results
The concentration of D-dimer in the group of patients with ulcerative colitis (UC) during remission ranged from 0.04 to 0.08 mcg/ml on average 0.06±0.01 mcg/ml, the concentration of IL-6 ranged from 4.6–21.3 pg/ml, the average value was 11.4 ± 0.2 pg/ml. A moderate correlation was established between the level of D-dimer and the concentration of IL-6 (r = 0.65; p &lt; 0.001) in UC patients during remission of the disease. The concentration of D-dimer in the group of patients with UC during the exacerbation period ranged from 1.0 to 3.8 mcg/ml on average 1.9±0.1 mcg/ml, the concentration of IL-6 ranged from 11.5–34.5 pg/ml, the average value was 18.95 ±0.8 pg/ml, which is significantly higher than during remission UC (p&lt; 0.001). A strong correlation was established between the level of D-dimer and the concentration of IL-6 (r=0.88; p&lt; 0.001) in UC patients during exacerbation.

Conclusion
In patients with UC during exacerbation, the concentration of D-dimer and IL-6 is significantly increased compared to the concentration of D-dimer and IL-6 during remission and has a strong correlation.
P0580 Efficacy and safety results of tulisokibart re-induction treatment in participants with ulcerative colitis in the Phase 2 ARTEMIS-UC clinical trial
Authors: Hoque PhD S S , Sands B E , Feagan B G , Yen M , Dong B , Zhou W , Danese S 
Published: January 2025

Abstract

Background
Tulisokibart is a monoclonal antibody that targets tumor necrosis factor-like cytokine 1A (TL1A), a regulator of inflammation and fibrosis in inflammatory bowel disorders such as ulcerative colitis (UC). The Phase 2 ARTEMIS-UC study demonstrated a significantly higher proportion of tulisokibart vs. placebo participants achieving clinical remission after 12 weeks of treatment1. This analysis evaluates the effects of re-induction treatment in participants who were non-responders during the initial 12-week induction period of the study.

Methods
Participants (≥18 years) of moderate to severe active UC, with conventional or advanced treatment failure, were randomized (1:1 ratio) to placebo or the 12-week induction treatment (intravenous tulisokibart 1000 mg, Day 1 and 500 mg, Weeks 2, 6, and 10). The study population consisted of 2 cohorts based on a genetic diagnostic test (Dx) assessing likelihood for responding to anti-TL1A treatment. Cohort 1 included participants stratified by Dx results while Cohort 2 included only Dx positive participants. Cohort 1 is the population used in these post-hoc analyses evaluating induction non-responders. Induction non-responders in either the tulisokibart or placebo groups were assigned to an open label 12-week re-induction with aforementioned induction dosing regimen (non-responders are defined as participants who did not achieve reduction of ≥2 points and ≥30% in modified Mayo score from baseline, accompanied by a reduction ≥1 in rectal bleeding sub score or absolute rectal bleeding sub score ≤1 at week 12). Efficacy and safety were assessed following the re-induction treatment at Week 26.

Results
In Cohort 1, 67 and 68 participants were randomized to receive placebo or tulisokibart induction treatment, respectively. At Week 14, 41 (placebo) and 21 (tulisokibart) induction non-responders entered re-induction and received 12-week open label tulisokibart treatment. At Week 26, 48% and 63% of participants who received initial 12-week of tulisokibart treatment (total 24-week tulisokibart treatment) and 63% and 76% of participants who received initial 12-week placebo treatment (total 12-week tulisokibart treatment) achieved symptomatic improvement and symptomatic response, respectively (Table). Re-induction with tulisokibart was well tolerated with no serious AEs or discontinuations due to AEs and no new safety signals (Table).

Conclusion
Re-induction treatment with tulisokibart is effective in participants who did not respond to initial induction treatment. Additionally, up to two tulisokibart induction regimens totaling 24 weeks is well tolerated with no new safety signals identified.

References
1.Sands et al. N Engl J Med 2024; 26;391(12):1119-1129
P0582 Do we need a Structured Transition Programme for patients with IBD? The Irish Experience
Authors: Doherty J , Hurley C , Girod P , Peacock J , Stallard L , Quinn S , Broderick A , Stenke E , Hussey S , Hartery K , Kevans D , O Donnell S , Slattery E , Cullen G , Doherty G , Murphy C , Bourke B , Dunne C 
Published: January 2025

Abstract

Background
The British Society of Gastroenterology recommend the use of structured transition programmes to improve control of chronic GI disease in adolescents. Although research is limited structured transition programmes have been shown to improve disease outcomes in IBD {1}.

Methods
We performed a retrospective multicentre study In collaboration with our National Children’s Hospital. Data was collected on patients prior to transition to adult services and after they transitioned to five adult hospitals across Ireland.
Our aim was to look at the impact of attending a structured transition programme on disease outcomes including need for escalation of medical therapy after transition to adult services, need for steroids, median FCP levels and engagement with services.
Patients were broken up into two groups: patients who attended a structured transition programme and our control patients who were transitioned with a referral letter to the adult gastroenterologist.

Results
In total 282 patients were included in our study. 155 attended a structured transition programme and 127 patients were transitioned with a written referral letter.
No significant differences were seen in basic demographics, median FCP levels or biologic use between either group at the time of transition to adult services. Patients who attended a structured transition programme had significantly lower rates of escalation of medical therapy after transition to adult services compared to our control cohort (38.8% versus 54.4%, p =0.012) (Figure 1). There was no significant difference seen in rates of biologic failure (p = 0.089), need for steroid (p = 0.35) or median FCP levels at 1 (p = 0.09) or 3 years (p = 0.30) between either group after transition to adult services.
Patients who took part in a structured transition programme did have significantly better engagement with adult IBD services with significantly lower rates of non-attendance at outpatient clinics in the 1st year after transition (11.6% versus 27.2%, p = 0.04) and significantly lower rates of disengagement with services (4.2% versus 13.1%, p = 0.015) (Figure 2).

Conclusion
Structured transition programmes in IBD improve disease outcome for patients and overall improve engagement with IBD services. More research and funding is required in the field of transition services in IBD to improve outcomes for patients long-term.

References
1.Brooks AJ, Smith PJ, Cohen R, Collins P, Douds A, Forbes V, et al. UK guideline on transition of adolescent and young persons with chronic digestive diseases from paediatric to adult care. Gut [Internet]. 2017;66(6):988–1000. Available from: http://dx.doi.org/10.1136/gutjnl-2016-313000